Bempegaldesleukin (NKTR-214) With Radiation and Anti-PD-1 Immunotherapy for Head and Neck Squamous Cell Carcinoma
Status:
Recruiting
Trial end date:
2026-06-01
Target enrollment:
Participant gender:
Summary
This trial will evaluate safety and efficacy of the combination of anti-PD1, NKTR-214, and
palliative radiation therapy in patients with recurrent or metastatic squamous cell carcinoma
of the head and neck. Twenty-four participants will be enrolled to evaluate the efficacy of
this combination.